Print

LAB21 Limited and IntegraGen, Inc. Partner to Develop New Colorectal Cancer Diagnostic  
2/22/2013 10:01:34 AM

CAMBRIDGE, England--(BUSINESS WIRE)--Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes. Under the agreement, Lab21 will develop a CE marked assay, using its proprietary SPARQâ„¢ PCR technology, to detect expression levels of a microRNA biomarker called hsa-mir-31-3p, which was discovered and patented by IntegraGen and its academic partners. Early research with this biomarker has shown that it may predict response to EGFR inhibitor therapy in KRAS-wild type patients who have metastatic colorectal cancer. Financial details were not disclosed.